Sanofi Makes Good On Outsourcing Promise In Deal With Covance
Executive Summary
Sanofi-Aventis’ multi-layered 10-year deal with the contract research organization Covance, announced September 30, 2010, is yet another sign of the pressure within Big Pharma to cut R&D costs even as it searches for new sources of innovation.
You may also be interested in...
Pharma: Serious About Change?
Pharmaceutical companies are attempting to solve unprecedented R&D and commercial challenges via business development, emphasizing cheaper, earlier-stage alliances and building up a base in emerging markets. An analysis of dealmaking trends from 2007 to 2010 shows big companies are embracing new kinds of partners, and shifting away from historic areas of interest to pursue hyper-specialty products and generics.
GSK Tries to Mimic Real-World Biotech
Not satisfied with its R&D experiments to date, GSK has taken its most radical step yet toward re-creating biotech within its walls: even smaller units complete with investment boards occupied by external VCs and CEOs and milestone-based funding and external VCs.
Alzheimer's Development Financing: Risky Therapies Call for Innovative Deals
Eli Lilly has hedged its bets on its two late-stage Alzheimer's disease candidates. In a deal with TPG-Axon and Quintiles' partnering group NovaQuest, Lilly sheds risk (and potentially reward) in this notoriously difficult therapeutic space. A model for private equity / pharma deals going forward?